ESTRO 2024 - Abstract Book

S2583

Clinical - Urology

ESTRO 2024

Conclusion:

Our preliminary results show that approaching PCa with five-fractions SBRT delivering a whole dose of 36.25 Gy and a focal 40 Gy SIB to the mpMRI/targeted biopsy-defined DILs is safe and effective, with excellent adherence to the planning protocol. Data collected on a median 16-months follow-up suggest that this treatment is not associated with an increased acute morbidity. Longer follow-up is needed to evaluate tumor control and late toxicity. In this respect, further enrollment of patients is ongoing.

Keywords: SBRT, prostate cancer, MRI-defined boost

References:

1. Gorovets D, Wibmer AG, Moore A, et al. Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion. EurUrol Oncol. 2022

2. Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial. J Clin Oncol. 2021

3. Draulans C, van der Heide UA, Haustermans K, et al. Primary endpoint analysis of the multicentre phase II hypo FLAME trial for intermediate and high-risk prostate cancer. Radiother Oncol. 2020

2901

Digital Poster

Multifocal MRI directed SBRT microboost for prostate cancer: early toxicity and EPIC QoL outcomes

Jonathan W. Lischalk 1 , Vianca F. Santos 1 , Meredith Akerman 2 , Astrid Sanchez 1 , Christopher Mendez 1 , Aaron Katz 3 , Anthony Corcoran 3 , Samir Taneja 4 , William C. Huang 4 , Moses M. Tam 1 , Todd J. Carpenter 1 , David J. Byun 5 , Anand Mahadevan 5 , Michael J. Zelefsky 5 , Jonathan A. Haas 1 1 Perlmutter Cancer Center at New York University Langone Hospital-Long Island, Department of Radiation Oncology, New York, USA. 2 NYU Long Island School of Medicine, Division of Health Services Research, Mineola, USA. 3 NYU Long Island School of Medicine, Department of Urology, Mineola, USA. 4 Perlmutter Cancer Center at New York University